乳腺癌组织褪黑素受体1和雌激素受体表达的相关性及其临床意义

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (2425 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨褪黑素受体1（MT1）和雌激素受体（ER）在乳腺癌组织中表达水平的相关性及其临床意义。方法: 采用免疫组化染色（SP）法检测90例乳腺浸润性导管癌、34例乳腺导管内癌和35例癌旁乳腺组织中MT1和ER的表达水平，并对其表达进行相关性分析。结果: ER、MT1在两组乳腺癌中的阳性表达率均高于其在癌旁乳腺组织中的阳性表达率，差异有统计学意义（P＜0.05）。在124例乳腺癌中，ER与MT1的表达均与组织学分级（P=0.036，P=0.015）、临床分期（P=0.014，P=0.021）及淋巴结转移（P=0.014，P=0.006）有相关性，差异有统计学意义。MT1与ER在乳腺浸润性导管癌、乳腺导管内癌组织中的表达呈负相关（r=-0.411,P=0.000;r=-0.454, P=0.007）。结论： MT1高表达和ER低表达与乳腺癌的发展和转归有关，联合检测MT1、ER的表达可为乳腺癌预后的判断及靶向治疗提供实验依据。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：褪黑素, 褪黑素受体1, 雌激素, 雌激素受体, 乳腺癌

Abstract：Objective: To discuss the correlation of expression level between melatonin receptor 1(MT1) and estrogen receptor (ER) in breast cancer tissue and its clinical significance. Methods：The expression of MT1, ER in 90 cases of invasive ductal breast cancer, 34 of intraductal breast cancer, 35 of the tissues near breast carcinoma were detected by immunohistochemical staining. The correlation of their expression were analyzed. Results：The positive rate of ER and MT1 expression in invasive ductal breast cancer and intraductal breast cancer were higher than those in the tissues near breast carcinoma. The difference had statistical significance( P＜0.05). The correlation of ER and MT1 expression was observed with histological grade (P=0.036，P=0.015）, clinical stage (P=0.014，P=0.021) and lymph node metastasis(P=0.014，P=0.006) in 124 cases of breast cancer. The results were statistically significant. Negative correlation was observed between the expression of MT1 and ER in invasive ductal breast cancer and intraductal breast cancer（r=-0.411, P=0.000;r=-0.454, P=0.007）.Conclusion：The expression of MT1 and ER in the breast cancer are correlated with the development and transfer of breast cancer. Combined detecting of their expression can provide experimental basis to be used for the prognostic judgment and targeted therapy of breast cancer.

收稿日期: 2012-12-11

基金资助:

镇江市社会发展基金资助项目（SH2007048）

通讯作者: 狄荣科，教授，硕士生导师，E-mail: dirongke@126.com

作者简介: 陈丽萍（1980—），女，硕士研究生

引用本文:

陈丽萍1，曾建1，陈淼1，许豪勤2，陈艳2，刘克坚2，狄荣科1. 乳腺癌组织褪黑素受体1和雌激素受体表达的相关性及其临床意义[J]. 江苏大学学报:医学版, 2013, 23(1): 57-60,64. CHEN Li-ping1, ZENG Jian1, CHEN Miao1,XU Hao-qin2, CHEN Yan2, LIU Ke-jian2, DI Rong-ke1. Expression of melatonin receptor 1 in human breast cancer and its correlation analysis. Journal of Jiangsu University(Medicine Edition), 2013, 23(1): 57-60,64.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2013/V23/I1/57

［1］吴菲,林国桢,张晋昕.我国恶性肿瘤发病现状及趋势[J].中国肿瘤,2012,21(2):81-85.

［2］ Li Y, Birnbaumer L, Teng CT.Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1[J].Mol Endocrinol,2010,24(5):969-980.

［3］ Parise CA, Bauer KR, Brown MM, et al.Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004[J].Breast J,2009,15(6):593-602.

［4］ Hill SM, Frasch T, Xiang S,et al.Molecular mechanisms of melatonin anticancer effects[J]. Integr Cancer Ther, 2009,8(4):337-346.

［5］ Cos S, González A, MartínezCampa C,et al. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions[J]. Cancer Detect Prev,2006,30(2):118-128.

［6］ Renoir JM.Estradiol receptors in breast cancer cells: associated co-factors as targets for new therapeutic approaches[J]. Steroids, 2012,77(12):1249-1261.

［7］ Gonzalez A, Cos S, MartinezCampa C, et al.Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells\[J\]. J Pineal Res,2008 ,45(1):86-92.

［8］ Treeck O, Haldar C, Ortmann O. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines[J]. Oncol Rep,2006,15(1):231-235.

［9］张燕,马天,马志乾，等.褪黑素对阿霉素抗雌激素受体阴性乳腺癌细胞MDAMB231作用的影响及其机制[J].中国肿瘤临床与康复，2011,18(6):503-507.

［10］ SanchezBarcelo EJ, Mediavilla MD, AlonsoGonzalez C,et al.Breast cancer therapy based on melatonin[J]. Recent Pat Endocr Metab Immune Drug Discov, 2012,6(2):108-116.

［11］ SánchezBarceló EJ, Cos S, Mediavilla D,et al.Melatonin-estrogen interactions in breast cancer[J]. J Pineal Res, 2005,38(4):217-222.

［12］ Abbasi S, Nouri M, Azimi C. Estrogen receptor genes variations and breast cancer risk in Iran[J]. Int J Clin Exp Med,2012,5(4):332-341.

［13］ Lai L, Yuan L, Cheng Q,et al．Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines[J].Breast Cancer Res Treat, 2009, 118(2):293-305.

［14］ Collins A，Yuan L，Kiefer TL，et al．Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice[J]. Cailcer Lett, 2003, 189(1):49-57.